About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.

CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology

Clinicaltrials.gov identifier NCT03940846

Recruitment Status Active, not recruiting

First Posted May 7, 2019

Last update posted April 6, 2020

Study Description

Brief summary:

Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually. Lung cancer is divided into two main groups: Small Cell Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC), with prevalence of ~20% and 80% respectively. NSCLC is further subdivided into adenocarcinoma (the most common), squamous cell carcinoma (SCC), and large cell carcinoma. Furthermore, each subtype is likely to have specific mutations, which could be targeted for treatment. Medical imaging and radiomics feature extraction represent a candidate alternative to conventional tissue biopsy, a theory that is investigated in this study.

  • Condition or Disease:Nonsmall Cell Lung Cancer
  • Intervention/Treatment: Diagnostic Test: Virtual biopsy
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 650 participants
  • Observational Model: Cohort
  • Time Perspective: Retrospective
  • Official Title: CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: October 2020
  • Estimated Study Completion Date: January 2021
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Maastro (Lung1)
Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
Diagnostic Test: Virtual biopsy
Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
: Radboud
A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
Diagnostic Test: Virtual biopsy
Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
: Stanford
Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
Diagnostic Test: Virtual biopsy
Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
: UCSF
A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
Diagnostic Test: Virtual biopsy
Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
Outcome Measures
  • Primary Outcome Measures: 1. Lung histology [ Time Frame: December 2019 ]
    Is the tumor under investigation an adenocarcinoma of the lung?
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients diagnosed with NSCLC, who further underwent tissue biopsy to determine tumor histology.
Criteria

Inclusion Criteria:

- Availability of diagnostic non-contrast enhanced CT scan.

- Availability of histologic tumor analysis results

Exclusion Criteria:

-

Contacts and Locations
Contacts
Locations

Netherlands, Limburg
Maastricht University
Maastricht

Sponsors and Collaborators

Maastricht University

University of California, San Francisco

Radboud University

More Information
  • Responsible Party: Maastricht University
  • ClinicalTrials.gov Identifier: NCT03940846 History of Changes
  • Other Study ID Numbers: LHist
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: April 6, 2020
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Adenocarcinoma
    Carcinoma, Non-Small-Cell Lung
    Adenocarcinoma of Lung